Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pre-clinical in vitro infection models.

George L Drusano1

  • 1Institute for Therapeutic Innovation, University of Florida, USA.

Current Opinion in Pharmacology
|October 17, 2017
PubMed
Summary

Optimizing antimicrobial dosing is crucial to combat resistance. In vitro models like the hollow fiber infection model (HFIM) help determine effective drug doses and schedules to maximize bacterial kill and minimize resistance.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of Aminoglycoside Dosing Regimens Adjusted for Renal Function and In Vitro Susceptibility Test Interpretive Criteria for Enterobacterales and <i>Pseudomonas aeruginosa</i>: Brief Summary.

Open forum infectious diseases·2025
Same author

Evaluation of Aminoglycoside Dosing Regimens Adjusted for Renal Function and In Vitro Susceptibility Test Interpretive Criteria for Enterobacterales and <i>Pseudomonas aeruginosa</i>.

Open forum infectious diseases·2025
Same author

Translating Pharmacokinetic-Pharmacodynamic Principles Into Improved Methodology for Clinical Trials That Compare Intermittent With Prolonged Infusion of Beta-Lactam Antibiotics.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025
Same author

Evaluation of a potent LpxC inhibitor for post-exposure prophylaxis treatment of antibiotic-resistant <i>Burkholderia pseudomallei</i> in a murine infection model.

Antimicrobial agents and chemotherapy·2024
Same author

US Food and Drug Administration, Centers for Disease Control and Prevention, and National Institutes of Health Co-Sponsored Public Workshop Summary-Development Considerations of Antimicrobial Drugs for the Treatment of Gonorrhea.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2024
Same author

Population pharmacokinetics and humanized dosage regimens matching the peak, area, trough, and range of amikacin plasma concentrations in immune-competent murine bloodstream and lung infection models.

Antimicrobial agents and chemotherapy·2024

Area of Science:

  • Pharmacodynamics
  • Antimicrobial Resistance
  • Infectious Diseases

Background:

  • Antimicrobial resistance is a significant global health threat, especially in hospitals.
  • Effective dosing strategies are essential for new antimicrobial agents to improve patient outcomes.

Purpose of the Study:

  • To highlight the importance of in vitro models in optimizing antimicrobial dosing and combating resistance.
  • To compare the utility of the 1-compartment model and the hollow fiber infection model (HFIM) for antimicrobial studies.

Main Methods:

  • Utilizing in vitro systems, including the 1-compartment model and HFIM.
  • Conducting dose fractionation studies to identify dynamically-linked indices for bacterial kill.
  • Performing studies in HFIM to assess regimens that suppress resistance emergence.

Main Results:

  • Both 1-compartment and HFIM can identify key indices for achieving bacterial kill.
  • HFIM is particularly effective for studying dosing regimens that prevent the emergence of antimicrobial resistance.

Conclusions:

  • In vitro models are invaluable for making rational decisions on antimicrobial dose and schedule selection.
  • The HFIM is the preferred model for investigating strategies to suppress antimicrobial resistance development.

Related Experiment Videos